News | July 21, 2014

Study Shows Malapposition Influences Death from Early Stent Thrombosis

stentys, stent, self-apposing stent

Stentys' Self-Apposing Stent

July 21, 2014 – Stentys announced the publication of an article in the Journal of the American College of Cardiology (JACC) entitled, "Causes of Early Stent Thrombosis in Patients Presenting with Acute Coronary Syndrome: An Ex Vivo Human Autopsy Study."
 
Researchers led by Renu Virmani, MD, of the CVPath Institute, examined autopsy cases of 67 stented coronary lesions from 59 patients who presented with acute coronary syndrome (ACS) and died within 30 days of stent implantation. They identified that 34 patients (58%) died from early stent thrombosis (ST). The authors found that the occurrence of malapposition, medial tear and necrotic core prolapse was greater in the early ST group than the non-ST group (34% vs. 18%, p=0.008, 27% vs. 15%, p=0.004, and 28% vs. 11%, p<0.001 respectively) and that they were independent risk factors associated to ST.
 
According to the authors: "While complete stent apposition may be important to avoid incomplete apposition in rupture-prone lesions, excess medial tear secondary to high inflation pressure was found to be a major determinant of early ST." 
 
The authors suggested that "improvement in implantation technique and refinement of stent design may improve clinical outcomes of ACS patients." 
 
When treating heart attack patients, cardiologists often cannot determine artery diameter with certainty because of the clot and vessel contraction. When selecting a conventional stent, they risk under-sizing (which can lead to malapposition) or over-sizing (which can cause vessel wall tear), and either scenario increases the likelihood of heart attack recurrence and death. 
 
Stentys’ Self-Apposing Stent is designed to adapt to the vessel’s unknown diameter, particularly in the post-infarction phase, in order to prevent the malapposition or excessive inflation problems associated with conventional stents. Results from Stentys' APPOSITION II clinical trial, published by JACC Cardiovascular Interventions in December 2012, showed 28% of malapposition in conventional stents three days after implant versus 0% for Stentys stents (p<0.001). 
 
Gonzague Issenmann, co-founder and Chief Executive Officer of Stentys said: "Dr. Virmani and her colleagues have confirmed that malapposition leads to serious complications for patients with acute coronary syndrome. The Self-Apposing Stent data not only shows greatly reduced rates of malapposition compared with conventional stents but also very low mortality rates." 
 
For more information: www.stentys.com/file_bdd/documents/1399469104_Stentys_JACC_PrVermani_PR.pdf 
 
Reference:
Nakano M, Yahagi K, Otsuka F, Sakakura K, Finn AV, Kutys R, Ladich E, Fowler DR, Joner M, Virmani R. "Causes of Early Stent Thrombosis in Patients Presenting with Acute Coronary Syndrome: An Ex Vivo Human Autopsy Study." Journal of the American College of Cardiology (2014), doi: 10.1016/j.jacc.2014.02.607. 

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init